FDA Approves VYVANSE(TM) (lisdexamfetamine Dimesylate), The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults

BASINGSTOKE, England and PHILADELPHIA, April 23 /PRNewswire/ -- - Within the First Eight Months Since its Introduction in the United States, VYVANSE has Achieved Over One Million Prescriptions - In a Clinical Study With Adults, VYVANSE was Shown to Significantly Improve the Symptoms of ADHD (Inattention, Hyperactivity and Impulsivity)(1)

Related Keywords

Maryland , United States , Rockville , Massachusetts , Philadelphia , Pennsylvania , Johns Hopkins University , Boston , American , Lisdexamfetamine Dimesylate , Matthew Emmens , Davidw Goodman , Shire Plc , Us Department Of Health , Adult Attention Deficit Disorder Center , Johns Hopkins University School Of Medicine , National Comorbidity Survey Replication , American Psychiatric Association , Psychometric Properties , Exchange Commission , Shire Pharmaceuticals Inc , Drug Administration , National Prescription Audit , Child Health , American Academy Of Child , Us Centers For Disease , First Eight Months Since , Achieved Over One Million , Clinical Study With Adults , Significantly Improve , Attention Deficit Hyperactivity Disorder , Chief Executive Officer , Johns Hopkins University School , Full Prescribing Information , Statistical Manual , Mental Disorders , Fourth Edition , Text Revision , Clinical Global Impressions Improvement , Disease Control , Private Securities Litigation Reform Act , Attention Deficit , Hyperactivity Disorder , Annual Report , Attention Deficit Hyperactvity , American Academy , Adolescent Psychiatry Annual Meeting , Prescription Audit , Teacher Ratings , Year Review , Scales Assessing , American Psychiatric Publishing , Attention Deficit Hyperactivity , Results From , National Comorbidity Survey , Investor Relations , Clea Rosenfeld , Eric Rojas , North America , Jessica Mann , Matthew Cabrey , Science Education Amp Policy ,